Show simple item record  

dc.contributor.authorOoi, Clementen_NZ
dc.contributor.authorSolanki, Kamalen_NZ
dc.contributor.authorLao, Chunhuanen_NZ
dc.contributor.authorFrampton, Chrisen_NZ
dc.contributor.authorWhite, Douglasen_NZ
dc.date.accessioned2017-07-26T00:11:08Z
dc.date.available2017en_NZ
dc.date.available2017-07-26T00:11:08Z
dc.date.issued2017en_NZ
dc.identifier.citationOoi, C., Solanki, K., Lao, C., Frampton, C., & White, D. (2017). Mortality in the Waikato Hospital Systemic Sclerosis Cohort. International Journal of Rheumatic Diseases, 47, Published online 4 June 2017.en
dc.identifier.issn1444-0903en_NZ
dc.identifier.urihttp://hdl.handle.net/10289/11220
dc.description.abstractObjective To characterize the causes of mortality and standardised mortality ratio in a cohort of patients with systemic sclerosis (SSc). Methods A cohort of 132 patients enrolled at the Waikato Systemic Sclerosis Clinic was prospectively followed from 2005 to 2016. Patient demographics, diagnoses and laboratory reports were used to assess risk of mortality and generate standardised mortality ratios (SMR). Survival was analyzed using Kaplan-Meier methods. Results Of the cohort of 132 patients, 20 (15%) were deceased by the end of the study period. The median age of diagnosis and death was 52 years (range 13–86) and 71 years (range 42–87) respectively. Seventy percent of deaths were SSc related and the leading causes of death were due to pulmonary arterial hypertension (PAH), interstitial lung disease (ILD) and scleroderma renal crisis (SRC). Patients diagnosed after the age of 60 had renal or cardiac manifestations and were associated with a significantly increased risk of mortality. The overall SMR was 2.59 (95% CI 1.67–4.01) and was higher in those with diffuse versus limited SSc (6.46, 95% CI 3.08–13.54 vs. 1.93, 95% CI 1.10–3.41) and males (4.17, 95% CI 1.74–10.02 vs. 2.30, 95% CI 1.39–3.81). Conclusion This study demonstrated an increased risk of mortality in patients with SSc relative to that of the general population. An excess in risk was observed particularly in those with diffuse SSc and in males. Renal and cardiac involvement were found to be significant indicators of mortality and reinforces the necessity of screening for these complications.
dc.language.isoenen_NZ
dc.publisherWileyen_NZ
dc.subjectScience & Technologyen_NZ
dc.subjectLife Sciences & Biomedicineen_NZ
dc.subjectMedicine, General & Internalen_NZ
dc.subjectGeneral & Internal Medicineen_NZ
dc.titleMortality in the Waikato Hospital Systemic Sclerosis Cohorten_NZ
dc.typeJournal Article
dc.relation.isPartOfInternational Journal of Rheumatic Diseasesen_NZ
pubs.begin-pagePublished online 4 June 2017
pubs.elements-id194564
pubs.organisational-group/Waikato
pubs.organisational-group/Waikato/2018 PBRF
pubs.organisational-group/Waikato/VICH
pubs.organisational-group/Waikato/VICH/2018 PBRF - VICH
pubs.publication-statusPublisheden_NZ
pubs.volume47en_NZ
dc.identifier.eissn1445-5994en_NZ


Files in this item

This item appears in the following Collection(s)

Show simple item record